What is Polatuzumab vedotin?
Polatuzumab can be employed to treat diffuse B-cell lymphoma after at least two other treatment treatments failed, had no effect, or ended their effectiveness. Polatuzumab is administered as a part of bendamustine (Bendeka, Treanda) and an anti-inflammatory drug that includes the drug rituximab (Rituxan). Polatuzumab Vedotin can also be employed for other purposes that are not covered in this guideline.
Side effects of Polatuzumab vedotin
Contact a medical professional immediately. If you are experiencing warning signs of an allergic response, such as symptoms of hives, difficulty breathing, or swelling of your lips, face, or tongue, Polatuzumab is a drug that can cause a grave cerebral infection, which could lead to the loss of a job or even death. Consult your physician immediately in case you are experiencing issues with your speech, thoughts, vision, speech, or muscle movement. The symptoms can begin slowly and become more severe. There are some side effects that can happen after the injection. Contact your physician when you are feeling irritable, itchy, cold, lightheaded, wheezing, chest tightness, or breathing difficulties within the first 24 hours following the injection.
Polatuzumab vedotin may cause serious side effects. Contact your physician immediately if you experience:
- bleeding or easy bruising (nosebleeds and bleeding gums);
- muscles are weak.
- cough with mucus sensation, chest pain, feeling out of breath;
- pale skin tone, pale skin, cold feet and hands and feet, feeling lightheaded;
- nerve issues: tingling, numbness, burning sensation, pain in your feet or hands and feet, as well as weakness and difficulty walking;
- symptoms of infection: fever nights sweats, mouth sores, cough, swelling of glands, breath that is shallow and burning or pain after you urinate, weight loss;
- symptoms of signs of shingles symptoms of shingles:-like symptoms, tingling, or a painful blistering symptoms of shingles, such as tingling or painful blistering on the body's side;
- Problems with the liver: loss of appetite and gastric discomfort (upper right side) and dark urine jaundice (yellowing of the eyes or skin)
- signs of tumor cell breakdown: confusion, weakness, muscle cramps, nausea, vomiting, fast or slow heart rate, decreased urination, tingling in your hands and feet, or around your mouth.
Common adverse effects of polatuzumab can include:
- fatigue, cough, fever, or other indications of infection
- nerve disorders nerve problems
- diarrhea Loss of appetite, diarrhea
This isn't an exhaustive list of possible side effects, and other side effects could occur. Contact your physician for advice regarding medical adverse effects. You may report any adverse reactions to the FDA at 1-800-FDA-1088.
Similar or related drugs
prednisone, rituximab, cyclophosphamide, rituxan, doxorubicin, and cytoxan
Warnings
Polatuzumab vedotin affects your immune system. It is possible to contract infections more often, including deadly or life-threatening infections. Consult your physician if you are suffering from a fever, chills or cough, or mouth sores, atypical bleeding, bruising or burning sensation when you pee, or have problems with your speech, thinking, or muscle movements.
Prior to use this drug
Speak to your doctor if you were ever diagnosed with:
- Liver disease or
- nerve issues (neuropathy) in your feet and hands.
Polatuzumab Vedotin may cause harm to an unborn baby as well as cause birth defects when either the father or mother is taking polatuzumab.
- If you're female, you may need to pass a negative pregnancy test prior to beginning this treatment. Do not take polatuzumab when you are expecting. Utilize the most effective contraception to avoid pregnancy while taking this medication and for at least three months following the last dose.
- If you're male, use effective birth control when your partner is capable of becoming pregnant. Use birth control for a minimum of five months following your last dose.
- Contact your physician immediately. If you become pregnant during the time that both the mother and father are taking polatuzumab,
This medicine can affect the fertility (ability to have kids) of males. But it is important to utilize birth control to avoid pregnancy since polatuzumab could harm a baby who is not yet born.
Avoid breastfeeding while taking this medication and at least two months after the last dose.
How to take Polatuzumab vedotin?
Polatuzumab Vedotin is administered as an infusion to the vein. Your healthcare professional will offer the injection. Polatuzumab Vedotin is typically administered once every 21 days, in addition to bendamustine and rituximab. Your physician will decide the time frame for treatment with these medications.
There are other medicines to prevent severe side effects such as allergic reactions and infections. Use these medicines for the duration your doctor prescribes. Polatuzumab vedotin affects your immune system. It is possible that you will contract infections more frequently, and even fatal or severe infections. Your blood needs to be tested frequently, and additional doses could be delayed based on the results.
Details on dosage
Usual Adult Dose for Lymphoma:
1.8 mg/kg every 21 days over 6 cycles, in combination with rituximab or bendamustine. Give this medication, along with bendamustine and rituximab, at any time at the beginning of the cycle.
The dose that is recommended for bendamustine for a day is 90 mg/m2 on days 1 and 2 of each cycle.
The dose recommended for Rituximab is 375 mg/m2 intravenous at the beginning of Day 1 of every cycle.
Comments:
Premedicate with an antihistamine as well as an antipyretic for at least 30 minutes prior to treatment.
Inject the first dose of this medication over a period of 90 minutes.
Monitor patients for reactions related to the infusion during the infusion and for at least 90 minutes after the completion of the initial dosage. If the previous dose was well tolerated, the next dose can be given as a 30-minute infusion, and patients must be observed throughout the infusion and for a minimum of 30 minutes following the completion of the infusion.
If a dose of this medication is missed, take it as promptly as you can. The schedule of administration should be adjusted to ensure a 21-day gap between doses.
Use: When combined with rituximab and bendamustine, a product to treat chronically relapsed or resistant massive B-cell lymphoma (DLBCL) that is not specifically stated following at least two prior treatments
What happens if I miss the dose?
Consult your physician for the appropriate treatment in the event that you don't make an appointment for a polatuzumab injection.
What happens if I overdose?
Because polatuzumab is administered by a medical specialist in a medical setting, the risk of overdose is low. to be observed.
What should be avoided?
Follow the instructions of your physician regarding any limitations on foods, drinks, or activities.
Interaction with other drugs
It is sometimes not recommended to take certain medications in combination. Certain medications can alter the blood levels of other medications that you take, which can cause more side effects or make the drugs less effective.
Polatuzumab is a vedotin derivative that can damage your liver, particularly when you are also taking specific medicines to treat depression, tuberculosis, and infections, birth control hormone replacement, the high level of cholesterol in your body, heart issues, and high blood pressure seizures or pain (including Tylenol, Advil, Motrin, or Aleve).
Other medications can affect polatuzumab Vedotin, such as medications that are prescribed and available over the counter, vitamins, and herbal products. Discuss with your physician all the medicines you are currently taking as well as any medicines you are about to start or stop taking.
